ReviewFrontiers in immunology2026

Immune-tumor cell ligand-receptor axes driving metabolic reprogramming and therapeutic resistance in cancer.

Hailin Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.